Company profile: Tome Biosciences
1.1 - Company Overview
Company description
- Provider of programmable gene insertion technologies, including Integrase-Mediated PGI using a proprietary integrase to integrate large DNA sequences (>1,000 bp) at user-defined genomic locations and Ligase-Mediated PGI using a DNA ligase for small sequence insertion, plus integrative gene therapies for PKU (PAH), ASCVD (ApoA-1), HCU (CBS), and hereditary hemochromatosis (HFE).
Products and services
- Integrase-Mediated PGI (I-PGI): Custom-engineered, programmable system integrating large DNA payloads (>1,000 base pairs) at user-defined genomic loci using a proprietary integrase for precise, stable gene addition
- Ligase-Mediated PGI (L-PGI): Enzyme-mediated platform inserting small DNA sequences (1–100s of base pairs) at user-selected genomic positions via DNA ligase for targeted, fine-scale integration
- Integrative Gene Therapy for ASCVD: Therapeutic-grade approach that increases ApoA-1 gene expression to treat atherosclerotic cardiovascular disease using gene insertion to elevate expression of the ApoA-1 gene.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tome Biosciences
Genelex
HQ: United States
Website
- Description: Provider of pharmacogenetic testing for precision medication management, backed by innovative analytics software, state-of-the-art laboratory facilities, and expert staff; a pioneer in DNA testing since 1987.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genelex company profile →
10x Genomics
HQ: United States
Website
- Description: Provider of an innovative genomics platform delivering spatial and single-cell multiomic solutions: Visium HD Spatial Gene Expression for whole transcriptome analysis at single cell-scale with continuous tissue coverage; Chromium Single Cell Gene Expression with multiomic options; Chromium Single Cell Immune Profiling with gene expression, cell surface proteins, and full-length paired BCR/TCR; and Xenium In Situ for subcellular single-molecule RNA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 10x Genomics company profile →
Devyser
HQ: Sweden
Website
- Description: Provider of diagnostic kits for complex DNA testing in oncology, hereditary diseases, and transplantation, used to guide targeted cancer therapies and enable genetic testing. Sold in 60+ countries, offerings include NGS-based tests for thalassemia, cystic fibrosis, familial hypercholesterolemia, thrombophilia, HFE mutations, and Y-chromosome microdeletions linked to male infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Devyser company profile →
Genomas
HQ: United States
Website
- Description: Provider of DNA-guided medicine products that bring personalized prescription of drugs to clinical practice, targeting treatments for mental illness, diabetes, and cardiovascular disease, and aimed at eliminating trial-and-error prescribing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomas company profile →
Epiontis
HQ: Germany
Website
- Description: Provider of immune cell identification and quantification services with accuracy and technical ease, using a novel molecular diagnostics technology, offering worldwide services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epiontis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tome Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tome Biosciences
2.2 - Growth funds investing in similar companies to Tome Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tome Biosciences
4.2 - Public trading comparable groups for Tome Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →